title: [Guidelines on "pharmacotherapy of neurodegenerative dementia": an update].
abstract: This article presents the evidence-based pharmacotherapeutic options for the most common forms of neurodegenerative dementia. The aim is to present the recommendations derived from the relevant studies on the neurological, psychiatric and geriatric practice of treatment for dementia patients. The text is derived from the 2009 guidelines of the German Society of Neurology (DGN, lead management: K. Fassbinder), the S3 guidelines of the DGN/German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN, lead management: G. Deuschl and W. Maier) and the latest amendments of the European Federation of Neurological Societies/European Society of Neurology (EFNS-ENS, Sorbi et al. Eur J Neurol 19:1159-1179, 2012) guidelines. The forms of neurodegenerative dementia addressed are Alzheimer's disease, frontotemporal dementia and Lewy body dementia. Specific statements on the treatment of dementia in Parkinson's disease and vascular dementia can be found in separate guidelines. An analogous article on psychosocial interventions was recently published in Der Nervenarzt (Kurz, Nervenarzt 84:93-103, 2013).
authors.affiliation: Neurologische Klinik, Universität des Saarlandes, 66424, Homburg, Deutschland, Klaus.fassbender@uks.eu.
authors.forename: K
authors.initials: K
authors.lastname: Fassbender
authors.forename: L
authors.initials: L
authors.lastname: Frölich
mesh_terms: D003704:Dementia / Q000188:drug therapy* / Q000209:etiology*; D005858:Germany; D006801:Humans; D019636:Neurodegenerative Diseases / Q000150:complications* / Q000188:drug therapy*; D009462:Neurology / Q000592:standards*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic
chemical_list: D018696:Neuroprotective Agents